Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269695 | 0.74 | MAPK1 (0.65) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL951841 | 0.72 | MAPK1 (0.63) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL269594 | 0.70 | GUCY1B2 (0.52) | MAPK1HCRTR1HCRTR2 | |
| SCHEMBL10512497 | 0.70 | MAPK1 (0.64) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL9516847 | 0.69 | MAPK1 (0.59) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL12012125 | 0.69 | MAPK1 (0.62) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL952278 | 0.68 | MAPK1 (1.00) | MAPK1ALOX15HCRTR1CYP1A2 | |
| Bromide SCHEMBL2334813 | 0.68 | MAPK1 (0.61) | MAPK1ALOX15HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL18357445 | 0.68 | MAPK1 (0.50) | MAPK1ALOX15 | |
| SCHEMBL20346954 | 0.67 | TP53 (0.52) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2094685-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008065626-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVESAS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | MAPK1 1409/4885ALOX15 1434/4885HCRTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.